CSL760
/ CSL Behring
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 18, 2021
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=12; Terminated; Sponsor: CSL Behring; Completed ➔ Terminated; For business reasons, not a safety issue
Clinical • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 16, 2021
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=12; Completed; Sponsor: CSL Behring; Active, not recruiting ➔ Completed; N=24 ➔ 12
Clinical • Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 20, 2021
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=24; Active, not recruiting; Sponsor: CSL Behring; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
February 15, 2021
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: CSL Behring; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
November 20, 2020
Pharmacokinetics, Safety, and Tolerability of CSL760, an Anti- COVID-19 Hyperimmune Intravenous Immunoglobulin, in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: CSL Behring
Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 5
Of
5
Go to page
1